|
|
Executives and Board
|
Thomas Callaway, M.D., M.B.A., Chief Executive Officer
|
After three years as an investor and board member, Dr. Callaway became the Chief Executive
Officer in April and is leading the commercial enterprise. He is a founding Partner of
Georgia
Venture Partners
and involved in all aspects of GVP investment activities. He is also founder
and president of
Life Science Partner.
A biotechnology executive, Dr. Callaway previously held
the position of Director of Commercial Development for SyStemix and marketing roles at
Roche Diagnostics and Roche Molecular Systems. He earned a medical degree from Vanderbilt
University School of Medicine. He holds an MBA and undergraduate degree from Duke
University.
|
P. Kathleen Lovell, BS/MAcc, Executive Chairman
|
Ms. Lovell is an angel investor and businesswoman with a mission, serving as
consultant, advisor, and hands-on business leader, helping early-stage
companies refine their business models, develop their infrastructure, access
capital and attain profitability. She has served in executive management,
marketing and operational capacities with a number of life sciences and
technology companies. Ms. Lovell is a member of angel investment
organization
Emergent Growth Fund, LLC.
|
Russell H. Plumb, MBA, Director
|
Mr. Plumb is President and Chief Executive Officer for
Inhibitex,
a clinical-stage
biopharmaceutical company developing products for the treatment and prevention of serious
infections. From August 2000 until December 2006, he served as Vice President, Finance and
Administration and Chief Financial Officer for the company. Prior to joining Inhibitex, Mr.
Plumb served as Chief Financial Officer for Emory Vision, a healthcare company. At
Serologicals Corporation, he was Vice President, Finance and Chief Financial Officer from 1994
to November 1999. Mr. Plumb received both a B. Comm. and a M.B.A. from the University of
Toronto.
|
John P. Richard, MBA, Director
|
Mr. Richard is a founding Partner of
Georgia Venture Partners
and is involved in all aspects of
GVP investment activities. Mr. Richard is also a strategic and commercial development advisor
to the biotechnology industry. He was previously Executive Vice President, Business
Development at SEQUUS Pharmaceuticals, Inc., where he was responsible for negotiating the
acquisition of SEQUUS by ALZA Corporation. Prior to joining SEQUUS, Mr. Richard headed
business development for VIVUS, Inc. and Genome Therapeutics Corporation (now Oscient),
where he was responsible for establishing numerous pharmaceutical alliances. He was also co-
founder and original CEO of IMPATH Laboratories, Inc., a leading cancer pathology reference
laboratory (now a part of Genzyme). Mr. Richard received his M.B.A. from Harvard Business
School and his B.S. from Stanford University.
|
|
|
